NCT03002779View on ClinicalTrials.gov

A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 26, 2017

Primary Completion Date

March 10, 2017

Study Completion Date

March 20, 2017

Conditions
Healthy
Interventions
DRUG

JNJ-53718678

Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.

Trial Locations (1)

9728 NZ

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03002779 - A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants | Biotech Hunter | Biotech Hunter